Japan Lifeline (7575) Fundamentals 2026 — P/E 10.4x, Revenue Analysis | SniperIQ
Japan Lifeline (7575) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥97.0B, trading at ¥1382.00 on the JPX. This SniperIQ fundamentals page covers Japan Lifeline's valuation (P/E 10.4x, P/B 1.5x), profitability (net margin 15.8%), revenue (¥59.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Japan Lifeline's market cap?
Japan Lifeline (7575) has a market capitalization of approximately ¥97.0B, trading at ¥1382.00 on the JPX. Market cap moves with the live share price.
What is Japan Lifeline's P/E ratio?
Japan Lifeline's trailing twelve-month P/E ratio is 10.4x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Japan Lifeline?
Japan Lifeline runs a net profit margin of 15.8%, a gross margin of 58.3%, and an operating margin of 20.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Japan Lifeline generate?
Japan Lifeline reported revenue of ¥59.2B for fiscal year 2025, with net income of ¥9.3B and earnings per share (EPS) of 133.3. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Japan Lifeline pay a dividend?
Japan Lifeline offers a trailing dividend yield of about 3.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Japan Lifeline financially healthy?
Japan Lifeline carries a debt-to-equity ratio of 0.05x and a current ratio of 3.61x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Japan Lifeline a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Japan Lifeline (7575) the key facts are: market cap ¥97.0B, P/E 10.4x, revenue ¥59.2B, 52-week range 1239-1645. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Japan Lifeline's full fundamentals live
Get Japan Lifeline's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.